Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOCRATES Test Kit Helps Develop First Metabolomics-Based Blood Test for Alzheimer’s

Published: Tuesday, March 18, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
The test is capable of predicting, with 90% accuracy, the risk of Alzheimer’s disease 2–3 years before it has actually become clinically manifest.

The findings, published in Nature Medicine, were generated using the validated AbsoluteIDQ® p180 test kit by Austrian BIOCRATES Life Sciences AG, a leading developer of innovative metabolomics solutions.

A team of researchers in Georgetown, Washington DC, and Rochester, New York, has developed the world’s first blood test capable of predicting Alzheimer’s disease. The first-of-its-kind study, recently published in Nature Medicine, used the AbsoluteIDQ® p180 test kit by BIOCRATES Life Sciences AG, a leading Austrian biotech company specialized in targeted metabolite quantification. 

Alzheimer’s disease currently affects more than 35 million individuals worldwide, and this figure is expected to increase to up to 150 million by 2050. A cure for Alzheimer’s disease is currently not available, but early detection could contribute to substantially improving the situation of affected individuals. While biomarkers have long been expected to provide important clues to the early causes of Alzheimer’s disease, current biomarkers are either invasive, time-consuming, or costly. The team around Mapstone and Federoff now discovered that a set of 10 lipids from peripheral blood predicts the development of mild cognitive impairment or Alzheimer’s disease with over 90% accuracy and 2–3 years in advance. Although it will take some time to develop test versions fit for use in doctors’ offices, the findings by Mapstone et al. are an impressive example of the power of metabolomics in diagnosis and biomarker discovery.

AbsoluteIDQ p180 provides extensive metabolic information from a single targeted assay, quantifying 186 analytes from 5 substance classes in a high-throughput manner. It features the advanced proprietary MetIDQ™ software solution, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice for researchers looking for a cost-effective solution to measure endogenous metabolites under quality-controlled conditions. The AbsoluteIDQ kits by BIOCRATES have been successfully applied in many different areas, including diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BIOCRATES Goes Spain and Turkey
Austrian diagnostic expert in personalized medicine continues to expand its European distribution network.
Thursday, May 10, 2012
BIOCRATES and Selexis Join Forces to Optimize High-yield Mammalian Cell Cultures
The agreement enables both the parties to combine their knowledge to help lower overall manufacturing costs for pharmacologically active proteins.
Tuesday, August 31, 2010
BIOCRATES Joins European Research Consortium – SysKid
The Company has joined a multi-partner European research program dedicated to improving the diagnosis and treatment of chronic kidney disease.
Thursday, April 01, 2010
BIOCRATES’ Metabolomics Expertise Provides New Insight into Functional Genomics
German researchers used Biocrates’ metabolomics expertise in research linking the genetic make-up of an individual to differences in their metabolism.
Tuesday, February 03, 2009
BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project
The latest framework six EU projects called COBRED will use technology platforms to find diagnostic biomarkers for two of the most common cancers, Colon and Breast Cancer.
Friday, May 11, 2007
Biocrates Raises €5 Million in Venture Financing
This investment further strengthens Biocrates’ position in the field of high content analysis and discovery of multiparametric biomarkers.
Thursday, June 29, 2006
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!